EUVIMEDEUVIMED entdecken
Crossref

[68Ga]Ga-AUNP-12 PET imaging to assess the PD-L1 status in preclinical and first-in-human study

Ming Zhou, Shijun Xiang, Yajie Zhao, Yongxiang Tang, Jinhui Yang, Xiaoqin Yin, Jie Tian iD, Shuo Hu, Yang Du

European Journal of Nuclear Medicine and Molecular Imaging · 2024

DOI: 10.1007/s00259-023-06447-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2024. Verfasst von Ming Zhou und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, 410008, China. Hauptthemen laut MEDLINE: Gallium Radioisotopes, Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: PD-L1 PET imaging, as a non-invasive procedure, can perform a real-time, dynamic and quantitative analysis of PD-L1 expression at tumor sites. In this study, we developed a novel peptide-based PET tracer, [68 Ga]Ga-AUNP-12, for preclinical and first-of-its-kind imaging of PD-L1 expression in patients. METHODS: Radiosynthesis of [68 Ga]Ga-AUNP-12 was conducted. Assays for cellular uptake and binding were conducted on the PANC02, CT26, and B16F10 cell lines. Preclinical models were used to investigate its biodistribution, imaging capacity, and pharmacokinetics. Furthermore, interferon-γ (IFN-γ) was used for development of an animal model with high PD-L1 expression for targeted PET imaging and efficacy evaluation of PD-L1 blocking therapy. In healthy volunteers and cancer patients, the PD-L1 imaging, radiation dosimetry, safety, and biodistribution were further evaluated. RESULTS: In vitro and in vivo animal studies showed that [68 Ga]Ga-AUNP-12 PET imaging displayed a high specificity in evaluating PD-L1 expression. The radiochemical yield of [68 Ga]Ga-AUNP-12 was 71.7 ± 8.2%. Additionally, its molar activity and radiochemical purity were satisfactory. The B16F10 tumor was visualized with the tumor uptake of 6.86 ± 0.71% ID/g and tumor-to-muscle ratio of 6.83 ± 0.36 at 60 min after [68 Ga]Ga-AUNP-12 injection. Furthermore, [68 Ga]Ga-AUNP-12 PET imaging could sensitively detect the PD-L1 dynamic changes in CT26 tumor xenograft models regulated by IFN-γ treatment, and correspondingly can effectively guide immunotherapy. Regarding radiation dosimetry, [68 Ga]Ga-AUNP-12 is safe for human use. The first human study found that [68 Ga]Ga-AUNP-12 can be rapidly cleared from blood and other nonspecific organs through the kidney excretion, leading to form a clear imaging contrast in the clinical framework. The specificity of [68 Ga]Ga-AUNP-12 was validated and tumor uptake strongly correlated with the high PD-L1 expression in patients with lung adenocarcinoma and oesophageal squamous cell carcinoma (OSCC). CONCLUSION: [68 Ga]Ga-AUNP-12 was successfully developed as a PD-L1-specific PET imaging tracer in preclinical and first-in-human studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gallium RadioisotopesNeoplasmsHumansB7-H1 AntigenCell Line, TumorPositron-Emission TomographyRadiopharmaceuticalsTissue Distribution

Stichwörter der Autor:innen

Immune checkpointsImmunotherapyPD-1/PD-L1PET/CT imaging

Substanzen

B7-H1 AntigenGallium RadioisotopesRadiopharmaceuticals

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, 410008, China.
  • CAS Key Laboratory of Molecular Imaging, Beijing Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, No. 95 Zhongguancun East Road, Beijing, 100190, China. jie.tian@ia.ac.cn.
  • Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, School of Medicine, Beihang University, No. 95 Zhongguancun East Road, Beijing, 100190, China. jie.tian@ia.ac.cn.
  • Department of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, 410008, China. hushuo2018@163.com.
  • National Clinical Research Center for Geriatric Disorders (Xiangya), Changsha, China. hushuo2018@163.com.
  • Key Laboratory of Biological Nanotechnology of National Health Commission, Xiangya Hospital, Central South University, 87 Xiangya Rd, Changsha, 410008, China. hushuo2018@163.com.

ORCID-Profile: Jie Tian

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhou, M., Xiang, S., Zhao, Y., Tang, Y., Yang, J., Yin, X., Tian, J., Hu, S., & Du, Y. (2024). [68Ga]Ga-AUNP-12 PET imaging to assess the PD-L1 status in preclinical and first-in-human study. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-023-06447-2

Vancouver

Zhou M, Xiang S, Zhao Y, Tang Y, Yang J, Yin X, et al. [68Ga]Ga-AUNP-12 PET imaging to assess the PD-L1 status in preclinical and first-in-human study. European Journal of Nuclear Medicine and Molecular Imaging. 2024. doi:10.1007/s00259-023-06447-2

BibTeX
@article{Zhou2024,
  author = {Zhou, Ming and Xiang, Shijun and Zhao, Yajie and Tang, Yongxiang and Yang, Jinhui and Yin, Xiaoqin and Tian, Jie and Hu, Shuo and Du, Yang},
  title = {[68Ga]Ga-AUNP-12 PET imaging to assess the PD-L1 status in preclinical and first-in-human study},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2024},
  doi = {10.1007/s00259-023-06447-2}
}
Kostenlos starten →